نتایج جستجو برای: bevacizumab

تعداد نتایج: 11192  

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2016
E Vrdoljak N Marschner C Zielinski J Gligorov J Cortes F Puglisi M Aapro L Fallowfield A Fontana M Inbar Z Kahan A Welt C Lévy E Brain X Pivot C Putzu A González Martín S de Ducla V Easton G von Minckwitz

BACKGROUND The randomised phase III TANIA trial demonstrated that continuing bevacizumab with second-line chemotherapy for locally recurrent/metastatic breast cancer (LR/mBC) after progression on first-line bevacizumab-containing therapy significantly improved progression-free survival (PFS) compared with chemotherapy alone [hazard ratio (HR) = 0.75, 95% confidence interval (CI) 0.61-0.93]. We ...

2016
Xingsheng Hu Ke Pu Xuqin Feng Shimin Wen Xi Fu Cuihua Guo Wenwu He

BACKGROUND Gemcitabine and pemetrexed have been used as maintenance therapy. However, few systematic reviews and meta-analyses have assessed their effects in the newest studies. This systematic review and meta-analysis were conducted to assess the role of gemcitabine and pemetrexed in the maintenance treatment of non-small-cell lung carcinoma (NSCLC). METHODS We performed a literature search ...

2012
Margarita Echavez

Objective: To determine the effect of intravitreally administered bevacizumab, alone or as adjunct to mitomycin-C, after trabeculectomy on bleb survival and histology in rabbit eyes. Methods: An experimental, interventional, comparative, animal study consisting of 16 rabbit eyes underwent trabeculectomy, 8 of which were enhanced with intra-operative mitomycin-C. Eyes were randomized to receive ...

Journal: :Surgical neurology 2008
Marlon S Mathews Mark E Linskey Anton N Hasso John P Fruehauf

BACKGROUND Bevacizumab is FDA approved to treat colon cancer and is currently used off label for metastatic breast, kidney, and lung cancers. Bevacizumab is a monoclonal antibody that binds to, and inactivates, VEGF and is believed to be antiangiogenic. CASE DESCRIPTION The authors report the case of a 54-year-old woman with metastatic infiltrating ductal breast carcinoma who developed left o...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Ryan S Turley Andrew N Fontanella James C Padussis Hiroaki Toshimitsu Yoshihiro Tokuhisa Eugenia H Cho Gabi Hanna Georgia M Beasley Christina K Augustine Mark W Dewhirst Douglas S Tyler

PURPOSE To investigate whether the systemically administered anti-VEGF monoclonal antibody bevacizumab could improve regional chemotherapy treatment of advanced extremity melanoma by enhancing delivery and tumor uptake of regionally infused melphalan (LPAM). EXPERIMENTAL DESIGN After treatment with systemic bevacizumab or saline, changes in vascular permeability were determined by spectrophot...

Journal: :Neurology 2008
A D Norden G S Young K Setayesh A Muzikansky R Klufas G L Ross A S Ciampa L G Ebbeling B Levy J Drappatz S Kesari P Y Wen

BACKGROUND Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, may have activity in recurrent malignant gliomas. At recurrence some patients appear to develop nonenhancing infiltrating disease rather than enhancing tumor. METHODS We retrospectively reviewed 55 consecutive patients with recurrent malignant gliomas who received bevacizumab and chemotherapy t...

Journal: :Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2013
Lin-Bo Cai Juan Li Ming-Yao Lai Chang-Guo Shan Zong-De Lian Wei-Ping Hong Jun-Jie Zhen Qing Zhou Li-Chao Wang

OBJECTIVE We retrospectively studied the efficacy of bevacizumab as salvage therapy for recurrent malignant glioma with a focus on the overall survival (OS). METHODS Patients who received a therapy other than surgery for recurrent malignant glioma were included. Efficacy was evaluated using MRI. Neurological function was evaluated using the Response Assessment in Neuro-Oncology (RANO). The su...

Journal: :European journal of ophthalmology 2008
H Faghihi R Roohipoor S-F Mohammadi K Hojat-Jalali A Mirshahi A Lashay N Piri Sh Faghihi

PURPOSE To evaluate the additive effect of triamcinolone to bevacizumab in comparison to standard macular laser photocoagulation versus bevacizumab in the management of diabetic macular edema (DME). METHODS In a prospective, randomized clinical trial, 130 eyes of 110 patients with type 2 diabetes with DME were included. Eligible eyes were randomly assigned to 1.25 mg intravitreal bevacizumab ...

2017
Bradley J. Monk Warner K. Huh Julie Ann Rosenberg Ira Jacobs

OBJECTIVE Bevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis inhibitors is limited. Biosimilars are large, structurally complex molecules that are intended to be highly similar to, and treat the same condition(s) as, an existing licensed o...

Journal: :Asian Pacific journal of cancer prevention : APJCP 2014
Li-Ming Zhu Ya-Zhen Zhao Hai-Xing Ju Lu-Ying Liu Lei Chen Bi-Xia Liu Qi Xu Cong Luo Jie-Er Ying Yun-Shan Yang Hai-Jun Zhong

OBJECTIVE To evaluate the efficacy and safety of bevacizumab in the treatment of patients with metastatic colorectal cancer (mCRC). METHODS In a single-center, observational study of 91 Chinese patients with mCRC who received bevacizumab in combination with chemotherapy was conducted. OBJECTIVE response rates (ORRs), progression-free survival (PFS), overall survival (OS) and adverse events we...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید